文献速递脑血管病外科神经重症

未破裂颅内动脉瘤的综合管理:一项全覆盖照护试验

Comprehensive Aneurysm Management (CAM): An All-Inclusive Care Trial for Unruptured Intracranial Aneurysms.
PubMed 文献 · World Neurosurg · 2020-06-09

在缺乏随机证据的情况下,未破裂颅内动脉瘤(UIA)的最佳管理仍不确定。CAM试验为全覆盖照护试验结合登记研究,将适合至少两种管理方案的患者1:1随机分配至保守或治愈性治疗,主要结局为10年无神经功能依赖生存(mRS<3)。

要点

  • CAM试验采用全覆盖照护结合登记设计,任何UIA患者(30天内无颅内出血史)均可入组。
  • 适合至少两种方案者随机分配至保守或治愈性治疗,用最小化法平衡动脉瘤大小≥7mm、位置和年龄<60岁。
  • 主要假设为积极治疗将10年合并神经病残与死亡(mRS>2)从24%降至16%。

核心结论

  • UIA患者可在全覆盖照护试验框架内接受综合管理。

研究设计与样本

  • CAM为全覆盖照护试验结合登记研究,任何UIA患者(30天内无颅内出血史)可入组。
  • 适合至少两种管理方案的患者按1:1随机分配至保守或治愈性治疗,用最小化法平衡动脉瘤大小≥7mm、位置(前/后循环)和年龄<60岁。

主要发现

  • 主要结局为10年无神经功能依赖生存(mRS<3)。
  • 次要结局包括随访期间蛛网膜下腔出血发生率及相关病残与死亡、UIA血管内或外科治疗1年病残与死亡、1/5/10年总体病残与死亡、住院时长及非家庭出院。
  • 随机部分主要假设为积极治疗将10年合并神经病残与死亡(mRS>2)从24%降至16%。

关键数值与推荐

  • 随机部分需在4年内从至少20个中心招募至少961例患者。

临床怎么用

  • 临床可依据CAM算法结合临床判断与随机化来分配UIA管理方案。
  • 适合至少两种管理方案的患者可考虑纳入随机分配以积累证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the absence of randomized evidence, the optimal management of patients with unruptured intracranial aneurysms (UIA) remains uncertain. METHODS: Comprehensive Aneurysm Management (CAM) is an all-inclusive care trial combined with a registry. Any patient with a UIA (no history of intracranial hemorrhage within the previous 30 days) can be recruited, and treatment allocation will follow an algorithm combining clinical judgment and randomization. Patients eligible for at least 2 management options will be randomly allocated 1:1 to conservative or curative treatment. Minimization will be used to balance risk factors, using aneurysm size (≥7 mm), location (anterior or posterior circulation), and age <60 years. RESULTS: The CAM primary outcome is survival without neurologic dependency (modified Rankin Scale [mRS] score <3) at 10 years. Secondary outcome measures include the incidence of subarachnoid hemorrhage during follow-up and related morbidity and mortality; morbidity and mortality related to endovascular treatment or surgical treatment of the UIA at 1 year; overall morbidity and mortality at 1, 5, and 10 years; when relevant, duration of hospitalization; and, when relevant, discharge to a location other than home. The primary hypothesis for patients randomly allocated to at least 2 options, 1 of which is conservative management, is that active UIA treatment will reduce the 10-year combined neurologic morbidity and mortality (mRS score >2) from 24% to 16%. At least 961 patients recruited from at least 20 centers over 4 years will be needed for the randomized portion of the study. CONCLUSIONS: Patients with unruptured intracranial aneurysms can be comprehensively managed within the context of an all-inclusive care trial.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Darsaut TE, Desal H, Cognard C, et al. Comprehensive Aneurysm Management (CAM): An All-Inclusive Care Trial for Unruptured Intracranial Aneurysms. World Neurosurg. 2020. PMID: 32526362. doi:10.1016/j.wneu.2020.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。